These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26932927)

  • 21. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
    J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
    Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
    Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of Dexlansoprazole Delayed-Release Capsules, a Dual Delayed-Release Proton Pump Inhibitor.
    Grady H; Murakawa Y; Mulford D; Kukulka M
    J Pharm Sci; 2019 Nov; 108(11):3496-3501. PubMed ID: 31386865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.
    Sharma P; Shaheen NJ; Perez MC; Pilmer BL; Lee M; Atkinson SN; Peura D
    Aliment Pharmacol Ther; 2009 Apr; 29(7):731-41. PubMed ID: 19183157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
    Chiang HH; Wu DC; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Yao CC; Tsai CE; Liang CM; Wang YK; Wang JW; Huang CF; Chuah SK;
    Drug Des Devel Ther; 2019; 13():1347-1356. PubMed ID: 31118571
    [No Abstract]   [Full Text] [Related]  

  • 26. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
    Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
    Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.
    Kukulka M; Wu J; Perez MC
    J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):41-7. PubMed ID: 21716130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
    Peura DA; Metz DC; Dabholkar AH; Paris MM; Yu P; Atkinson SN
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1010-21. PubMed ID: 19735233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.
    Lee RD; Vakily M; Mulford D; Wu J; Atkinson SN
    Aliment Pharmacol Ther; 2009 Apr; 29(8):824-33. PubMed ID: 19243357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proton pump inhibitors in the management of gastroesophageal reflux disease.
    Hrelja N; Zerem E
    Med Arh; 2011; 65(1):52-5. PubMed ID: 21534455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
    Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.
    Gold BD; Pilmer B; Kierkuś J; Hunt B; Perez MC; Gremse D
    Dig Dis Sci; 2017 Nov; 62(11):3059-3068. PubMed ID: 28916953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.
    Liang CM; Kuo MT; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Wang HM; Yao CC; Tsai CE; Wang YK; Wang JW; Huang CF; Wu DC; Chuah SK;
    World J Gastroenterol; 2017 Dec; 23(47):8395-8404. PubMed ID: 29307999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 4 Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole.
    Wu JCY; Sheu BS; Wu MS; Lee YC; Choi MG
    J Neurogastroenterol Motil; 2020 Jan; 26(1):85-95. PubMed ID: 31597230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Causes of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux disease in Asia.
    Kinoshita Y; Ishihara S
    Therap Adv Gastroenterol; 2008 Nov; 1(3):191-9. PubMed ID: 21180528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease.
    Kukulka M; Nudurupati S; Perez MC
    Clin Exp Gastroenterol; 2014; 7():461-71. PubMed ID: 25525378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dexlansoprazole is Effective in Relieving Heartburn during the Fasting Month of Ramadan.
    Rimmani HH; Rustom LBO; Rahal MA; Shayto RH; Chaar H; Sharara AI
    Dig Dis; 2019; 37(3):188-193. PubMed ID: 30625462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unmet treatment needs of gastroesophageal reflux disease in Asia: gastroesophageal reflux disease in Asia Pacific survey.
    Goh KL; Choi MG; Hsu WP; Chun HJ; Mahachai V; Kachintorn U; Leelakusolvong S; Kim N; Rani AA; Wong BC; Wu J; Chiu CT; Chu R; Shetty V; Bocobo JC; Chan MM; Lin JT
    J Gastroenterol Hepatol; 2014 Dec; 29(12):1969-75. PubMed ID: 24990817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HISTORICAL PERSPECTIVE OF GASTROESOPHAGEAL REFLUX DISEASE CLINICAL TREATMENT.
    Zaterka S; Marion SB; Roveda F; Perrotti MA; Chinzon D
    Arq Gastroenterol; 2019 Aug; 56(2):202-208. PubMed ID: 31460587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule.
    Kukulka M; Nudurupati S; Perez MC
    Therap Adv Gastroenterol; 2016 Nov; 9(6):770-780. PubMed ID: 27803732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.